These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 34520436)
1. Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells. Furugaki K; Harada N; Yoshimura Y Anticancer Drugs; 2022 Feb; 33(2):124-131. PubMed ID: 34520436 [TBL] [Abstract][Full Text] [Related]
2. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death. Kawauchi D; Takahashi M; Satomi K; Yamamuro S; Kobayashi T; Uchida E; Honda-Kitahara M; Narita Y; Iwadate Y; Ichimura K; Tomiyama A Cancer Sci; 2021 Jun; 112(6):2442-2453. PubMed ID: 33728771 [TBL] [Abstract][Full Text] [Related]
3. Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines. Chen Y; Ma G; Su C; Wu P; Wang H; Song X; Yu Q; Zeng A; Zhou S Anticancer Drugs; 2018 Nov; 29(10):935-943. PubMed ID: 30074936 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells. Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637 [TBL] [Abstract][Full Text] [Related]
5. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613 [TBL] [Abstract][Full Text] [Related]
6. Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance. Liu D; Xu X; Wen J; Zhang C; Fan M Lung Cancer; 2021 Oct; 160():32-35. PubMed ID: 34391065 [TBL] [Abstract][Full Text] [Related]
7. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914 [TBL] [Abstract][Full Text] [Related]
8. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534 [TBL] [Abstract][Full Text] [Related]
9. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK. Liu L; Hou F; Liu Y; Li W; Zhang H J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318 [TBL] [Abstract][Full Text] [Related]
10. Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer. Kodama T; Tsukaguchi T; Satoh Y; Yoshida M; Watanabe Y; Kondoh O; Sakamoto H Mol Cancer Ther; 2014 Dec; 13(12):2910-8. PubMed ID: 25349307 [TBL] [Abstract][Full Text] [Related]
11. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer. Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177 [TBL] [Abstract][Full Text] [Related]
12. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243 [TBL] [Abstract][Full Text] [Related]
13. cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma. Berberich A; Schmitt LM; Pusch S; Hielscher T; Rübmann P; Hucke N; Latzer P; Heßling B; Lemke D; Kessler T; Platten M; Wick W J Neurooncol; 2020 Jan; 146(1):9-23. PubMed ID: 31776900 [TBL] [Abstract][Full Text] [Related]
14. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report. Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158 [TBL] [Abstract][Full Text] [Related]
15. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells. Tani T; Yasuda H; Hamamoto J; Kuroda A; Arai D; Ishioka K; Ohgino K; Miyawaki M; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K Mol Cancer Ther; 2016 Jan; 15(1):162-71. PubMed ID: 26682573 [TBL] [Abstract][Full Text] [Related]
16. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant. Song P; Zhang J; Shang C; Zhang L Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144 [TBL] [Abstract][Full Text] [Related]
17. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. Kogita A; Togashi Y; Hayashi H; Banno E; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K Int J Oncol; 2015 Mar; 46(3):1025-30. PubMed ID: 25502629 [TBL] [Abstract][Full Text] [Related]
18. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review. Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785 [TBL] [Abstract][Full Text] [Related]
19. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer. Gadgeel SM Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761 [TBL] [Abstract][Full Text] [Related]
20. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer. Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]